Modeling Alzheimer's Disease Progression Using Disease Onset Time and Disease Trajectory Concepts Applied to CDR-SOB Scores From ADNI

Disease‐onset time (DOT) and disease trajectory concepts were applied to derive an Alzheimer's disease (AD) progression population model using the clinical dementia rating scale—sum of boxes (CDR‐SOB) from the AD neuroimaging initiative (ADNI) database. The model enabled the estimation of a DOT and a disease trajectory for each patient. The model also allowed distinguishing fast and slow‐progressing subpopulations according to the functional assessment questionnaire, normalized hippocampal volume, and CDR‐SOB score at study entry. On the basis of these prognostic factors, 81% of the mild cognitive impairment (MCI) subjects could correctly be assigned to slow or fast progressers, and 77% of MCI to AD conversions could be predicted whereas the model described correctly 84% of the conversions. Finally, synchronization of the biomarker‐time profiles on estimated individual DOT virtually expanded the population observation period from 3 to 8 years. DOT‐disease trajectory model is a powerful approach that could be applied to many progressive diseases.

[1]  Tim Schultz,et al.  Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes. , 2013, British journal of clinical pharmacology.

[2]  Andrew C. Hooker,et al.  Modeling Subpopulations with the $MIXTURE Subroutine in NONMEM: Finding the Individual Probability of Belonging to a Subpopulation for the Use in Model Analysis and Improved Decision Making , 2009, The AAPS Journal.

[3]  Kaori Ito,et al.  Disease progression meta-analysis model in Alzheimer's disease , 2010, Alzheimer's & Dementia.

[4]  V. Lobanov,et al.  An Improved Model for Disease Progression in Patients From the Alzheimer's Disease Neuroimaging Initiative , 2012, Journal of clinical pharmacology.

[5]  Mark E. Schmidt,et al.  The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.

[6]  A. Dale,et al.  CSF Biomarkers in Prediction of Cerebral and Clinical Change in Mild Cognitive Impairment and Alzheimer's Disease , 2010, The Journal of Neuroscience.

[7]  Mark E. Schmidt,et al.  The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.

[8]  Terry L. Jernigan,et al.  Changes in volume with age—consistency and interpretation of observed effects , 2005, Neurobiology of Aging.

[9]  Nick C. Fox,et al.  A meta-analysis of hippocampal atrophy rates in Alzheimer's disease , 2009, Neurobiology of Aging.

[10]  Keith A. Johnson,et al.  Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer’s disease , 2011, Alzheimer's & Dementia.

[11]  Nick C Fox,et al.  Hippocampal atrophy rates in Alzheimer disease , 2009, Neurology.

[12]  Jieping Ye,et al.  Sparse learning and stability selection for predicting MCI to AD conversion using baseline ADNI data , 2012, BMC Neurology.

[13]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[14]  Mark E. Schmidt,et al.  The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans , 2010, Alzheimer's & Dementia.

[15]  Rudi Verbeeck,et al.  Quantifying the pathophysiological timeline of Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[16]  R. Tibshirani,et al.  Generalized Additive Models , 1986 .

[17]  Bruno Vellas,et al.  Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer’s disease trials , 2011, Alzheimer's & Dementia.

[18]  Sébastien Ourselin,et al.  Head size, age and gender adjustment in MRI studies: a necessary nuisance? , 2010, NeuroImage.

[19]  Kaori Ito,et al.  Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database , 2011, Alzheimer's & Dementia.

[20]  Joseph V. Hajnal,et al.  A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T) , 2010, NeuroImage.

[21]  J. Trojanowski,et al.  Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.